SAN FRANCISCO and SUZHOU, China, June 15, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic,...
Hence then, the article about innovent announces completion of first participant dosed in the seventh phase 3 clinical trial glory osa of mazdutide in china was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China )
Also on site :
- Lukashenko claims he warned Putin about assassination attempt
- Rose Parade 2026 awards announced: Top honor goes to Cal Poly Universities
- Kristi Noem, Stephen Miller Dance to & 039;Ice Ice Baby& 039; at New Year& 039;s Eve Party